Publication:
A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.

Simple item page
dc.contributor.authorVishwanathan, Karthick
dc.contributor.authorSanchez-Simon, Inmaculada
dc.contributor.authorKeam, Bhumsuk
dc.contributor.authorPenel, Nicolas
dc.contributor.authorde Miguel-Luken, Maria
dc.contributor.authorWeilert, Doris
dc.contributor.authorMills, Andrew
dc.contributor.authorMarotti, Marcelo
dc.contributor.authorJohnson, Martin
dc.contributor.authorRavaud, Alain
dc.date.accessioned2023-02-09T09:35:54Z
dc.date.available2023-02-09T09:35:54Z
dc.date.issued2020
dc.description.abstractOsimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. In this phase I study, we assessed the effects of normal renal function (NRF) and severe renal impairment (SRI) on the pharmacokinetics (PK) of osimertinib in patients with solid tumors. Part A: patients with NRF (creatinine clearance [CrCL] ≥90 mL/min), and SRI, (CrCL
dc.identifier.doi10.1002/prp2.613
dc.identifier.essn2052-1707
dc.identifier.pmcPMC7307240
dc.identifier.pmid32567817
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307240/pdf
dc.identifier.unpaywallURLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.613
dc.identifier.urihttp://hdl.handle.net/10668/15791
dc.issue.number4
dc.journal.titlePharmacology research & perspectives
dc.journal.titleabbreviationPharmacol Res Perspect
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.page.numbere00613
dc.pubmedtypeClinical Trial, Phase I
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectepidermal growth factor receptors
dc.subjectkidney
dc.subjectnon-small cell lung cancer
dc.subjectosimertinib
dc.subjectpharmacokinetics
dc.subjectrenal disposition
dc.subjecttyrosine kinase inhibitors
dc.subject.meshAcrylamides
dc.subject.meshAdministration, Oral
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAniline Compounds
dc.subject.meshAntineoplastic Agents
dc.subject.meshArea Under Curve
dc.subject.meshFemale
dc.subject.meshHepatic Insufficiency
dc.subject.meshHumans
dc.subject.meshKidney Function Tests
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshSeverity of Illness Index
dc.titleA multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number8
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC7307240.pdf
Size:
1.49 MB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía